VESELSKÁ, Renata, Marta JEŽOVÁ, Michal KÝR, Pavel MAZÁNEK, Petr CHLAPEK, Viera DOBROTKOVÁ and Jaroslav ŠTĚRBA. Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy. Frontiers in Oncology. Lausanne: Frontiers Media SA, vol. 9, NOV 15, p. 1-12. ISSN 2234-943X. doi:10.3389/fonc.2019.01221. 2019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy
Authors VESELSKÁ, Renata (203 Czech Republic, guarantor, belonging to the institution), Marta JEŽOVÁ (203 Czech Republic, belonging to the institution), Michal KÝR (203 Czech Republic, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Petr CHLAPEK (203 Czech Republic, belonging to the institution), Viera DOBROTKOVÁ (703 Slovakia, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution).
Edition Frontiers in Oncology, Lausanne, Frontiers Media SA, 2019, 2234-943X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.848
RIV identification code RIV/00216224:14310/19:00108600
Organization unit Faculty of Science
Doi http://dx.doi.org/10.3389/fonc.2019.01221
UT WoS 000501273700001
Keywords in English HOXC9; NF1; PBX1; immunohistochemistry; neuroblastoma; predictive markers; prognostic markers
Tags 14110230, 14110321, podil
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/2/2020 11:49.
Abstract
The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is one of the important aspects that may provide precision in the prediction of a patient's clinical outcome. Our study was designed as a detailed comparative analysis of five selected proteins (DDX39A, HMGA1, HOXC9, NF1, and PBX1) in one cohort of patients using the same methodical approaches. These proteins were already reported separately as related to the resistance or sensitivity to retinoids and as useful prognostic markers of survival probability. In the cohort of 19 patients suffering from high-risk neuroblastomas, we analyzed initial immunohistochemistry samples obtained by diagnostic biopsy and post-induction samples taken after the end of induction therapy. The expression of DDX39A, HMGA1, HOXC9, and NF1 showed varied patterns with almost no differences between responders and non-responders. Nevertheless, we found very interesting results for PBX1: non-responders had significantly higher expression levels of this protein in the initial tumor samples when compared with responders; this expression pattern changed inversely in the post-induction samples, and this change was also statistically significant. Moreover, our results from survival analyses reveal the prognostic value of PBX1, NF1, and HOXC9 expression in neuroblastoma tissue. In addition to the prognostic importance of PBX1, NF1, and HOXC9 proteins, our results demonstrated that PBX1 could be used for the prediction of the clinical response to induction chemotherapy in patients suffering from high-risk neuroblastoma.
Links
MUNI/A/1586/2018, interní kód MUName: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials" (Acronym: Personalizovaná léčba v dětské onkologii)
Investor: Masaryk University, Category A
NV15-34621A, research and development projectName: Kandidátní biomarkery rezistence k retinoidům u dětí s vysoce rizikovými neuroblastomy
PrintDisplayed: 16/4/2024 13:32